Inclusion Criteria:

- Signed written informed consent.

- Registration and treatment in a clinical trial with L BLP25 under sponsorship of
Merck KGaA / EMD Serono / Merck Serono Japan (feeder trial). [Note, subjects who have
been allocated to treatments not containing L BLP25 in the feeder trial are eligible
for this trial and will be followed-up for PD (if applicable) and survival.]

- End of Treatment procedures have been performed in the feeder trial.

Additional inclusion criteria also apply.

Exclusion Criteria

- Pregnancy and lactation period; women of childbearing potential, unless using
effective contraception as determined by the Investigator. Subjects whom the
Investigator considers may be at risk of pregnancy will have a pregnancy test
performed per institutional standard.

- Known hypersensitivity to any of the trial treatment ingredients (if applicable).

- Legal incapacity or limited legal capacity.

- Any other reason that, in the opinion of the Investigator, precludes the subject from
participating in the trial.

Additional exclusion criteria also apply.